Abstract
Invasive fungal infections (IFI) remain a major cause of morbidity and mortality in patients (pts) undergoing HCT. The epidemiology of IFI has changed, with a higher proportion of mould infections reported compared to earlier reports (Marr et al. Clin Infect Dis. 2002). The incidence of IFI in children undergoing HCT has been reported at a range of 1.6-25%. The changes in epidemiology of IFI are attributed to multiple factors, including corticosteroid treatment, graft-versus-host disease (GVHD), increase in transplants from alternative donors, and emergence of resistance with use of azoles for IFI prevention.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
